Výsledky vyhledávání - "Marta, Compte"

Akademický článek

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses

Autor: Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona, Patricia Iglesias-Hernández, Saray Aragón-García, Anaïs Jiménez-Reinoso, Marta Compte, Shaukat Khan, Takeshi Tsuda, Patrick Chames, Javier Lacadena, Luis Álvarez-Vallina, Laura Sanz

Publikováno v: OncoImmunology, Vol 13, Iss 1 (2024)

T cell-based immunotherapies for solid tumors have not achieved the clinical success observed in hematological malignancies, partially due to the immunosuppressive effect promoted by the tumor microenvironment, where PD-L1 and TGF-β play a pivotal r

Externí odkaz: https://doaj.org/article/3126feeb469c436b90c0b4d00590133a

Zobrazit plný text záznamu

Akademický článek

Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity

Autor: Laura Rubio-Pérez, Susana Frago, Marta Compte, Rocío Navarro, Seandean L. Harwood, Rodrigo Lázaro-Gorines, Marina Gómez-Rosel, Oana Hangiu, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Luis Álvarez-Vallina

Publikováno v: Antibodies, Vol 13, Iss 2, p 34 (2024)

Immune checkpoint blockade has changed the treatment paradigm for advanced solid tumors, but the overall response rates are still limited. The combination of checkpoint blockade with anti-4-1BB antibodies to stimulate tumor-infiltrating T cells has s

Externí odkaz: https://doaj.org/article/f4146a3dc0ce4049b9e43fa900b61edb

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response

Publikováno v: OncoImmunology, Vol 12, Iss 1 (2023)

ABSTRACTImmune checkpoint blockade (ICB) with antibodies has shown durable clinical responses in a wide range of cancer types, but the overall response rate is still limited. Other effective therapeutic modalities to increase the ICB response rates a

Externí odkaz: https://doaj.org/article/87732fe8a8464638935a3dfe1b8c3ab0

Zobrazit plný text záznamu

Akademický článek

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Autor: Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina, Laura Sanz

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trial

Externí odkaz: https://doaj.org/article/50e1a9f6bc804a1eacd6d85e57eda00b

Zobrazit plný text záznamu

Akademický článek

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity

Publikováno v: iScience, Vol 25, Iss 9, Pp 104958- (2022)

Summary: Costimulation of tumor-infiltrating T lymphocytes by anti-4-1BB monoclonal antibodies (mAbs) has shown anti-tumor activity in human trials, but can be associated with significant off-tumor toxicities involving FcγR interactions. Here, we in

Externí odkaz: https://doaj.org/article/c486f101097e4624bed914bc95a337c3

Zobrazit plný text záznamu

Akademický článek

TGF‐β‐induced IGFBP‐3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion

Autor: Rocío Navarro, Antonio Tapia‐Galisteo, Laura Martín‐García, Carlos Tarín, Cesáreo Corbacho, Gonzalo Gómez‐López, Esther Sánchez‐Tirado, Susana Campuzano, Araceli González‐Cortés, Paloma Yáñez‐Sedeño, Marta Compte, Luis Álvarez‐Vallina, Laura Sanz

Publikováno v: Molecular Oncology, Vol 14, Iss 10, Pp 2609-2628 (2020)

The crosstalk between cancer cells and the tumor microenvironment has been implicated in cancer progression and metastasis. Fibroblasts and immune cells are widely known to be attracted to and modified by cancer cells. However, the role of pericytes

Externí odkaz: https://doaj.org/article/c3b7566f3dc541ee8b0ca0a826b2226f

Zobrazit plný text záznamu

Akademický článek

Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR

Autor: Marta Compte, Seandean L. Harwood, Jorge Martínez-Torrecuadrada, Gema Perez-Chacon, Patricia González-García, Antonio Tapia-Galisteo, Paul M. P. Van Bergen en Henegouwen, Aránzazu Sánchez, Isabel Fabregat, Laura Sanz, Juan M. Zapata, Luis Alvarez-Vallina

Publikováno v: Frontiers in Immunology, Vol 11 (2021)

Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been ha

Externí odkaz: https://doaj.org/article/73fed565702c4bd49e60af922d155683

Zobrazit plný text záznamu

Akademický článek

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)

Cancer therapy using systemically administrated 4-1BB-targeting antibodies is often associated with severe toxicity due to the nonspecific activation of autoreactive T cells. Here, the authors have developed a trimeric antibody targeting both 4-1BB a

Externí odkaz: https://doaj.org/article/7575acc4586f44568954b0510de1f6d3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání